AMAL develops peptide/protein-based therapeutic vaccines based on a proprietary technology platform called KISIMA®
Through new research collaborations and partnerships with pharmaceutical and biotech companies as well as academia and clinics, we aim to fully leverage our KISIMA® based technology with cutting edge science and advance research and development in immuno-oncology.
Discuss collaboration opportunities Learn more about KISIMA®
We have signed an exclusive patent license agreement with the University of Minnesota and the University of Geneva for different components of KISIMA®.
We also have a research collaboration agreement with the University of Tübingen and ongoing collaborations with academic groups and KOLs to further explore the potential of our KISIMA® platform, including the Geneva University, the HUG (Hopitaux Universitaires de Genève), the Fox Chase Cancer Center, the Istituto Oncologico Veneto, and the MD Anderson Cancer Center.